R&D Strategies of Pharmaceutical Companies and Current Status of CRO/SMO 2024

Language:
Japanese
Product Code No:
C66112600
Issued In:
2024/09
#of Pages:
157
Publication Cycle:
  
Format:
PDF

Price

150,000 yen ($976.88)
(excluding consumption tax)
300,000 yen ($1,953.76)
(excluding consumption tax)
450,000 yen ($2,930.64)
(excluding consumption tax)
* Equivalent value in US$ (Today's rate : $1= 153.55 yen , 2025/02/14 Japan)
*Scope of Each License Type

Coverage: (Product/service)

R&D Strategies of Pharmaceutical Companies

Research Target:

Pharmaceutical Companies,CRO companies, SMO companies

Research Content:

I. R&D Strategies of Pharmaceuticals and Actual Status & Perspective of CRO/SMO

1. R&D Strategies of Pharmaceuticals
2. Actual Status & Perspective of CRO
3. Actual Status & Perspective of SMO


II. R&D Strategies of Leading Pharmaceuticals 

1. Astellas Pharma Inc.
2. AstraZeneca K.K.
3. Eisai Co., Ltd.
4. Otsuka Holdings Co., Ltd.
5. ONO PHARMACEUTICAL CO., LTD.
6. Kyowa Kirin Co., Ltd.
7. Sanofi K.K.
8. Sumitomo Pharma Co., Ltd.
9. SHIONOGI & CO., LTD.
10. DAIICHI SANKYO COMPANY, LIMITED
11. Takeda Pharmaceutical Company Limited.
12. Mitsubishi Tanabe Pharma Corporation
13. CHUGAI PHARMACEUTICAL CO., LTD.
14. Eli Lilly Japan K.K.
15. Novartis Pharma K.K.
16. Bayer Yakuhin, Ltd.


III. Strategies of CRO Companies and SMO Companies

1. M3, Inc.
2. CMIC HOLDINGS Co., Ltd.
Plus, brief profiles of leading CROs (29 enterprises) and leading SMOs (22 enterprises)

 

Price

written in Japanese
150,000 yen ($976.88)
(excluding consumption tax)
300,000 yen ($1,953.76)
(excluding consumption tax)
450,000 yen ($2,930.64)
(excluding consumption tax)
* Equivalent value in US$ (Today's rate : $1= 153.55 yen , 2025/02/14 Japan)
*Scope of Each License Type